News

Serve You Rx Named a Top Workplace for 2024

Pharmacy Benefit Manager Prioritizes Flexibility and Work-Life Balance for Its EmployeesMILWAUKEE, WI / ACCESSWIRE / April 29, 2024 / Serve…

2 years ago

Nava Health Continues Expansion With Opening Of New Location in Plantation, Florida

Second South Florida Location Strengthens Southern Presence COLUMBIA, MD / ACCESSWIRE / April 29, 2024 / Nava Health, a leader…

2 years ago

FREmedica Partners With CellCore at ECO24

VANCOUVER, BC / ACCESSWIRE / April 29, 2024 / Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ) is excited…

2 years ago

Hypha Labs Names Craig Ellins Chief Science Officer

LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Hypha Labs, Inc. (OTC Pink:DIGP) has announced that it has…

2 years ago

Specialty Revenue Cycle Management Firms Revolutionize Complex Claims Processing Through Automation, Garnering Rapid Adoption Among Providers, Black Book Survey

Black Book surveyed nearly 5,000 healthcare providers in a sweeping study of the evolving revenue cycle management IT sector. EnableComp…

2 years ago

Planet 13 Announces OMMU Approval for Proposed Sale of Planet 13 Florida and Acquisition of VidaCann

LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13" or the "Company"),…

2 years ago

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…

2 years ago

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the…

2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3…

2 years ago